Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 3/20 | 0.31 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17337133 | 0.90 | RAB9A (0.35) | RAB9AALDH1A1SMN1; SMN2MEN1HTT | |
| SCHEMBL17337541 | 0.90 | RAB9A (0.35) | RAB9AALDH1A1SMN1; SMN2MEN1HTT | |
| SCHEMBL17336943 | 0.88 | PARP1 (0.32) | RAB9ASMYD3PARP1 | |
| SCHEMBL17337046 | 0.88 | PARP1 (0.32) | RAB9ASMYD3PARP1 | |
| SCHEMBL23129903 | 0.87 | L3MBTL1 (0.32) | RAB9A | |
| SCHEMBL17337333 | 0.87 | L3MBTL1 (0.32) | RAB9A | |
| SCHEMBL18797959 | 0.86 | SMYD3 (0.39) | SMYD3PARP1 | |
| SCHEMBL17337288 | 0.86 | AAK1 (0.36) | PARP1 | |
| SCHEMBL17337083 | 0.86 | AAK1 (0.36) | PARP1 | |
| SCHEMBL17336990 | 0.86 | PARP1 (0.34) | RAB9ASMYD3PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008346-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200361962-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
| US-9637504-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160264598-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008346-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | HDAC6 2734/4885RAB9A 1933/4885SMYD3 926/4885 |
| US-20200361962-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | HDAC6 2734/4885RAB9A 1933/4885SMYD3 926/4885 |
| US-20160264598-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | HDAC6 2734/4885RAB9A 1933/4885SMYD3 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.